The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has announced its confirmed Board officers for 2026, following elections conducted during the organization’s December 2025 Board meeting, marking a notable achievement for the still young global initiative as it advances its role in promoting scientifically sound, human‑relevant alternatives to animal testing in cosmetics safety evaluation, with the newly appointed leadership illustrating both continuity and the increasing sophistication of ICCS as it builds on a year of meaningful advancements and prepares to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS operates at the nexus of science, policy, and cooperative action, uniting varied stakeholders who pursue the shared goal of advancing the worldwide shift toward animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers highlights the organization’s commitment to preserving strategic direction as it navigates an increasingly intricate global landscape, where expectations surrounding ethical research, scientific precision, and regulatory coherence continue to advance.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from the cosmetics, consumer goods, and regulatory advocacy sectors, emphasizing the multi‑stakeholder framework that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been reappointed as Chair of the Board of Directors. His continued term signals enduring confidence in a leadership approach grounded in scientific rigor, cross‑border cooperation, and constructive engagement with regulatory authorities.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement offers a valuable blend of regional insight and policy expertise. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing extensive knowledge of regulatory toxicology and international product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing significant leadership experience in toxicology and organizational governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Advancing animal-free science through collaboration
ICCS’ mission is grounded in the belief that animal-free safety assessment methods, once thoroughly optimized and validated, are not only ethically responsible but also capable of delivering exceptional scientific outcomes. Since its founding in early 2023, ICCS has worked to demonstrate that non-animal approaches can produce reliable, relevant data that protect both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining strength, supported by tangible progress and growing involvement from regulators worldwide.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong emphasis on maintaining ongoing dialogue. Throughout 2025, the organization engaged in wide-ranging interactions with regulators, scientists, and policymakers across multiple regions, guiding discussions on how animal‑free data might be assessed and integrated into existing regulatory frameworks. These exchanges have been essential in building shared understanding and trust, particularly in areas where the incorporation of non‑animal methodologies is still progressing.
A pivotal moment for cosmetics safety regulation
The installation of the 2026 Board officers takes place during a phase marked by notable transformations in global cosmetics regulations, as many markets reassess long‑standing testing standards in response to public expectations, scientific advancements, and new international policy trends, and within this shifting environment, organizations like ICCS remain vital in aligning innovation with regulatory requirements to ensure that progress continues to be both reliable and sustainable.
ICCS leadership has consistently emphasized that the transition to animal-free safety science cannot be achieved through isolated efforts. Instead, it requires coordinated action across industry, academia, regulators, and civil society. The composition of the Board reflects this philosophy, bringing together leaders who understand the technical, regulatory, and organizational dimensions of change.
Statements from ICCS leadership after the elections expressed both assurance and realism, highlighting the advances made in recent years while acknowledging that significant hurdles remain. They noted that securing broad regulatory approval for animal-free methods will continue to require ongoing research funding, transparent data exchange, and steady cooperation with authorities to respond to legitimate questions about reliability, practical applicability, and the protection of public health.
The re-elected Chair highlighted how crucial it is to harness ICCS’ global, multi-stakeholder framework to narrow the divide between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applicable tools that regulators can confidently use.
Reinforcing the groundwork for lasting influence
As ICCS looks toward 2026 and the years to follow, the organization stays dedicated to expanding its impact while reinforcing its achievements. The newly appointed Board leadership is anticipated to play a central role in shaping priorities that blend scientific ambition with practical implementation. This includes identifying fields that need additional direction or agreement, advancing the validation and spread of new methodologies, and promoting global harmonization to reduce inconsistencies in regulatory expectations.
Education stands as another fundamental component of ICCS’ strategy. By offering accessible, science-grounded materials and spaces for dialogue, the organization seeks to clarify animal-free safety science and support well-informed choices. This remains crucial in a discipline where misunderstandings or uneven knowledge can hinder advancement, even when the core science is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
By confirming its 2026 Board officers, ICCS underscores stability while hinting at ongoing advancement, with its leadership team providing steady direction after a year marked by concrete achievements and the seasoned perspective needed to guide the next stage of transformation; as scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a unifying hub and driving force for animal-free cosmetics safety science is set to become even more influential.
Ultimately, the significance of the 2026 Board elections arises not only from who is chosen but also from the message their leadership sends: a sustained commitment to collaboration, scientific rigor, and the careful advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to convert vision into lasting outcomes, guiding the future of cosmetics safety in a way that unites ethics, science, and global public trust.
